Genistein
- Generic Name
- Genistein
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10O5
- CAS Number
- 446-72-0
- Unique Ingredient Identifier
- DH2M523P0H
- Background
An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.
...
- Indication
Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.
- Associated Conditions
- Calcium Deficiency, Deficiency, Vitamin D, Osteodystrophy, Osteomalacia, Osteoporosis
- Associated Therapies
- -
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06634108
- Locations
- 🇨🇦
London Regional Health Science Centre, London, Ontario, Canada
Cardiovascular Genistein Therapy for Heart Failure Inflammation
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 40
- Registration Number
- NCT06501768
- Locations
- 🇸🇮
UMC Ljubljana, Ljubljana, Slovenia
Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT02766478
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 4
- Registration Number
- NCT02624388
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Genistein in Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Sofya Pintova
- Target Recruit Count
- 13
- Registration Number
- NCT01985763
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 36
- Registration Number
- NCT01489813
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Department of Urology, Atlanta, Georgia, United States
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT01325311
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2008-09-30
- Lead Sponsor
- University Hospital, Aker
- Target Recruit Count
- 47
- Registration Number
- NCT00546039
- Locations
- 🇳🇴
Aker University Hospital, Oslo, Norway
Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women
- Conditions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- University of Messina
- Target Recruit Count
- 400
- Registration Number
- NCT00355953
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00290758
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.